Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
NEW YORK, Aug. 15, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) between January 14, 2016 and July 26, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Shanawaz v. Intellipharmaceutics International Inc., et al. (Case No. 1:17-cv-05761) in the USDC for the Southern District of New York. Click here to view the complaint. To get more information go to:
http://www.zlk.com/pslra-sbm/intellipharmaceutics-international-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Intellipharmaceutics failed to conduct a human abuse liability study to support its Rexista New Drug Application (“NDA”); (2) the Company did not include abuse-deterrent studies conducted to support abuse-deterrent label claims related to abuse of the drug by various pathways; (3) the Company was not submitting sufficient data to support approval of the NDA; and (4) as a result, Defendants’ statements about Intellipharmaceutics’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
On July 27, 2017, shares of Intellipharmaceutics fell when the FDA released a report disclosing that “The safety information collected in the pharmacokinetic studies was of limited value…”
If you suffered a loss in Intellipharmaceutics you have until September 29, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
